CANY
CYTK icon

Caxton Associates (New York)’s Cytokinetics CYTK Stock Holding History

Caxton Associates (New York)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,486
Closed -$432K – 553
2021
Q4 		$432K Buy
+9,486
New +$366K 0.04% 316
2020
Q2 		– Sell
-13,175
Closed -$155K – 496
2020
Q1 		$155K Buy
+13,175
New +$168K 0.03% 368

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Caxton Associates (New York)'s CYTK Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Cytokinetics (CYTK) in Q1 2022, closing a stake of 9,486 shares — an estimated $432K sold.

Caxton Associates (New York) first reported a position in CYTK in Q1 2020 and held it in 2 quarters. The position peaked at $432K in Q4 2021. 240 funds tracked by Wall St. Rank hold CYTK as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Cytokinetics position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 9,486 Cytokinetics shares in Q1 2022, an estimated $432K.
  • Caxton Associates (New York) first reported a position in Cytokinetics in Q1 2020 and held it in 2 quarters.
  • Caxton Associates (New York)'s Cytokinetics position peaked at $432K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.